Immunotherapies for Bladder Cancer: a New Hope
Overview
Authors
Affiliations
Purpose Of Review: We review recent data on immunotherapies for bladder cancer and discuss strategies to maximize the antitumor effect of immunotherapy in solid tumors.
Recent Findings: Anti-programmed death ligand 1 has shown promise in advanced bladder cancer. Clinical trials of immune checkpoint inhibitors as monotherapy or in combination are underway. Here we review strategies for enhancing antitumor immunity using immunomodulating agents or combination treatments that may increase tumor response.
Summary: Combining immune checkpoint inhibitors with other treatment modalities may lead to the development of new treatment strategies in advanced bladder cancer; however, identifying predictive biomarkers is essential for appropriate patient selection.
Immunobiology of cancer stem cells and their immunoevasion mechanisms.
Marzban H, Pedram N, Amini P, Gholampour Y, Saranjam N, Moradi S Mol Biol Rep. 2023; 50(11):9559-9573.
PMID: 37776412 DOI: 10.1007/s11033-023-08768-9.
Guo R, Wang L, Bai S, Kang D, Zhang W, Ding Z Sci Rep. 2023; 13(1):12801.
PMID: 37550396 PMC: 10406853. DOI: 10.1038/s41598-023-39208-0.
Lu Y, Ho C, Hong J, Kuo M, Liao Y, Jaw F Mol Oncol. 2023; 17(8):1613-1627.
PMID: 36931723 PMC: 10399716. DOI: 10.1002/1878-0261.13422.
Zhu L, Liu X, Zhang W, Hu H, Wang Q, Xu K BMC Cancer. 2022; 22(1):556.
PMID: 35581573 PMC: 9112551. DOI: 10.1186/s12885-022-09606-0.
Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective.
Donini C, Rotolo R, Proment A, Aglietta M, Sangiolo D, Leuci V Cells. 2021; 10(3).
PMID: 33806296 PMC: 8001974. DOI: 10.3390/cells10030543.